Summary
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland.
Documents
- NICE TA - Nivolumab for treating advanced (unresectable or metastatic) melanoma - Section 75 Questionnaire
- NICE TA - Nivolumab for treating advanced (unresectable or metastatic) melanoma - Section 75 Questionnaire
Consultation description
On 1 July 2006 the Department established links with NICE whereby all technology appraisals and clinical guidelines published from that date are locally reviewed for applicability to Northern Ireland and, where appropriate, are endorsed for implementation in health and social care. THE LOCAL REVIEW DOES NOT REASSESS THE CLINICAL AND COST EVIDENCE USED BY NICE IN FORMING ITS ADVICE. This link has ensured that Northern Ireland has access to up-to-date, independent, professional, evidence-based guidance on the value of health care interventions.
Guidance for the consultation can be found on the NICE website
The HSC (SQSD) 2/13 circular provides details of the process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.
In order to meet the timescales set out in the circular, the closing date for responses is Thursday 3rd March 2016.
This Information will be used to inform the Equality Screening
Ways to respond
Consultation closed — responses are no longer being accepted.